Dermatology

Login Register

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Home

astellas-pharma

Tag: astellas pharma

Read all Latest developments and news on and about Astellas-Pharma

Astellas Pharma is an affiliate of Tokyo-based Astellas Pharma Inc. Committed to turning innovative science into medical solutions that bring value - Latest developments

Zydus Settles Mirabegron Patent Dispute With Astellas for USD 120 Million

sheeba farhat13 Feb 2026 3:31 PM IST

New Delhi: Zydus Lifesciences has entered into a settlement agreement with Astellas Pharma Inc. to resolve ongoing patent litigation in the United...

Lupin Appoints Dr Kushkumar Thakare as Manager, Medical Affairs for India Region

Lupin Settles Mirabegron Patent Dispute With Astellas for USD 90 Million, Clears US Sales

sheeba farhat10 Feb 2026 8:00 PM IST

Under the agreement, Lupin and its U.S. unit will pay Astellas a USD 75 million upfront payment and per-unit licensing fees on Mirabegron sales...

Pfizer Awards Rs 60 Lakh Each to 14 Healthtech Startups Under INDovation 2025

Padcev plus Keytruda significantly improves survival for certain patients with bladder cancer when given before, after surgery: Pfizer

Ruchika Sharma17 Aug 2025 10:30 AM IST

New York: Pfizer Inc. and Astellas Pharma Inc. have announced positive topline results from the Phase 3 EV-303 clinical trial (also known as...

Zydus receives final approvals from USFDA

Zydus Loses Patent Battle Over Bladder Drug Myrbetriq In US, Jury Trial Set for 2026

Farhat Nasim17 April 2025 6:55 PM IST

New Delhi: Indian drugmaker Zydus Lifesciences has received a legal setback in the United States after the District Court of Delaware ruled in favour...

FDA approves zolbetuximab with chemotherapy for treatment of Gastric and gastroesophageal cancer

Dr. Kamal Kant Kohli24 Oct 2024 6:00 AM IST

U.S. Food and Drug Administration (FDA) has approved VYLOY (zolbetuximab-clzb) in combination with fluoropyrimidine- and platinum-containing...

EMA validates Type II variation application for Padcev with Keytruda for first line treatment of advanced Bladder Cancer: Pfizer

Ruchika Sharma28 Jan 2024 10:00 AM IST

Tokyo: Astellas Pharma Inc. and Pfizer Inc. have announced that the European Medicines Agency (EMA) has validated for review a Type II...

USFDA nod to Padcev plus Keytruda for certain patients with Bladder cancer: Pfizer, Astellas Pharma

USFDA nod to Pfizer, Astellas Pharma Xtandi for early prostate cancar

Ruchika Sharma17 Nov 2023 12:30 PM IST

Tokyo: Pfizer Inc. and Astellas Pharma Inc. have announced that the companies have received approval from the U.S. Food and Drug Administration...

Pfizer gets USFDA priority review for prostate cancer drug Xtandi

Ruchika Sharma26 Aug 2023 12:00 PM IST

XTANDI (enzalutamide) is an androgen receptor signaling inhibitor.

FDA approves avacincaptad pegol intravitreal solution for treatment of geographic atrophy

Dr. Kamal Kant Kohli7 Aug 2023 11:00 AM IST

The US Food and Drug Administration (FDA) has granted approval to avacincaptad pegol (IZERVAY) for treatment of geographic atrophy (GA) secondary to...

Pfizer Sells ViiV Stake for USD 1.9 Billion, Shionogi Emerges Bigger Partner

Pfizer, Astellas Pharma' Xtandi combo therapy cuts risk of metastasis, death by 58 percent in prostate cancer

Ruchika Sharma2 May 2023 12:30 PM IST

XTANDI (enzalutamide) is an androgen receptor signaling inhibitor.

XTANDI plus Leuprolide improves Metastasis-Free survival in men with non-metastatic prostate cancer: Pfizer

Ruchika Sharma20 March 2023 11:50 AM IST

XTANDI (enzalutamide) is an androgen receptor signaling inhibitor.

Pfizer, Bristol Myers, AbbVie drugs likely to face US price negotiation

Ruchika Sharma14 March 2023 3:30 PM IST

Novo Nordisk's diabetes drug Ozempic, prostate cancer treatment Xtandi from Astellas Pharma and Pfizer, and J&J's blood thinner Xarelto are on three...

Journal Club Today

Health News Today

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok